SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001479290-22-000071
Filing Date
2022-05-13
Accepted
2022-05-13 18:17:26
Documents
1
Period of Report
2022-05-04

Document Format Files

Seq Description Document Type Size
1 FORM 4/A wf-form4a_165248019122400.html 4/A  
1 FORM 4/A wf-form4a_165248019122400.xml 4/A 4468
  Complete submission text file 0001479290-22-000071.txt   5881
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Issuer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O INTERMUNE, INC. 3280 BAYSHORE BOULEVARD BRISBANE CA 94005
Business Address
Russell Angus C. (Reporting) CIK: 0001534002 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-36297 | Film No.: 22924460